(NASDAQ: CRNX) Crinetics Pharmaceuticals's forecast annual revenue growth rate of 513% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Crinetics Pharmaceuticals's revenue in 2025 is $760,000.On average, 8 Wall Street analysts forecast CRNX's revenue for 2025 to be $480,860,107, with the lowest CRNX revenue forecast at $262,304,364, and the highest CRNX revenue forecast at $855,767,988. On average, 8 Wall Street analysts forecast CRNX's revenue for 2026 to be $4,272,376,009, with the lowest CRNX revenue forecast at $2,352,308,064, and the highest CRNX revenue forecast at $10,190,805,582.
In 2027, CRNX is forecast to generate $18,622,392,002 in revenue, with the lowest revenue forecast at $6,192,256,593 and the highest revenue forecast at $30,444,168,647.